[
  {
    "ts": "2025-06-24T16:45:47+00:00",
    "headline": "Vertex Pharmaceuticals Presents “Unprecedented” Data for T1D Cell Therapy Zimislecel, Shows Durable Benefit",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex Pharmaceuticals announced the simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880). Zimislecel is an investigational stem cell-derived, fully differentiated islet cell therapy […]",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-presents-unprecedented-data-164547578.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "d779908c-4168-3882-b243-f3814d74888a",
      "content": {
        "id": "d779908c-4168-3882-b243-f3814d74888a",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Presents “Unprecedented” Data for T1D Cell Therapy Zimislecel, Shows Durable Benefit",
        "description": "",
        "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex Pharmaceuticals announced the simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880). Zimislecel is an investigational stem cell-derived, fully differentiated islet cell therapy […]",
        "pubDate": "2025-06-24T16:45:47Z",
        "displayTime": "2025-06-24T16:45:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Vertex Pharmaceuticals Presents \"Unprecedented\" Data for T1D Cell Therapy Zimislecel, Shows Durable Benefit",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l0DSaAhjgYrGYMIp84u.Dg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MOpM93.qarjxsgAhhmtxCQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-presents-unprecedented-data-164547578.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-presents-unprecedented-data-164547578.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]